SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
🔥 科研通第二届『
应助活动周
』正在进行中,3月24-30日求助秒级响应🚀,千元现金等你拿。
当前排名🏆
📚 中科院2025期刊分区📊 已更新
畅快夏天
Lv2
102 积分
2024-04-25 加入
最近求助
最近应助
互助留言
Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer
2天前
已完结
Targeted inhibition of MASTL kinase activity induces apoptosis in breast cancer
3天前
已完结
2066-LB: Potential to Optimize Weight Loss with Enobosarm—Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat
5天前
已完结
The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition
7天前
已完结
The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition
8天前
已完结
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
1个月前
已完结
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
1个月前
已完结
Outlook for medicines development and use in 2025
1个月前
已完结
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
1个月前
已完结
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
1个月前
已完结
没有进行任何应助
感谢
2天前
感谢
3天前
感谢
3天前
感谢
3天前
感谢
7天前
点赞
1个月前
点赞
1个月前
点赞
1个月前
点赞
1个月前
感谢
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论